<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1804">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555096</url>
  </required_header>
  <id_info>
    <org_study_id>COV-4419-201</org_study_id>
    <nct_id>NCT04555096</nct_id>
  </id_info>
  <brief_title>A Trial of GC4419 in Patients With Critical Illness Due to COVID-19</brief_title>
  <official_title>A Pilot, Randomized, Placebo-Controlled Trial of GC4419 (Avasopasem Manganese) in Patients With Critical Illness Due to SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Trial of GC4419 in Patients with Critical Illness due to COVID-19&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Active GC4419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4419</intervention_name>
    <description>180 Minute IV Infusion</description>
    <arm_group_label>Active GC4419</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>180 Minute IV Infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects at least 18 years of age.&#xD;
&#xD;
          2. Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
          3. Laboratory-confirmed SARS-CoV-2 infection as determined by a positive PCR test&#xD;
             documented prior to randomization&#xD;
&#xD;
          4. Requirement for intensive inpatient hospital care&#xD;
&#xD;
          5. Acute hypoxemic respiratory failure typifying ARDS&#xD;
&#xD;
          6. Adequate liver function&#xD;
&#xD;
          7. Use of effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Expected survival for less than 48 hours after randomization&#xD;
&#xD;
          2. Child-Pugh stage C hepatic impairment and/or portal hypertension secondary to&#xD;
             cirrhosis&#xD;
&#xD;
          3. Stage IV chronic kidney disease or end-stage kidney disease on maintenance&#xD;
             hemodialysis&#xD;
&#xD;
          4. Requirement for extra-corporeal membrane oxygenation (ECMO)&#xD;
&#xD;
          5. Acute Myocardial Infarction (AMI)&#xD;
&#xD;
          6. Active bleeding requiring transfusion&#xD;
&#xD;
          7. Concurrent participation in another clinical trial of experimental treatment for&#xD;
             SARSCoV-2&#xD;
&#xD;
          8. Female patients who are pregnant or breastfeeding&#xD;
&#xD;
          9. Requirement for concurrent treatment with nitrates&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Study Chair</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Sanders</last_name>
    <phone>610-725-1500</phone>
    <email>info@galeratx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jon Holmlund, MD</last_name>
    <phone>610-725-1500</phone>
    <email>info@galeratx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Teresi</last_name>
      <phone>319-384-7546</phone>
    </contact>
    <investigator>
      <last_name>Lakshmi Durairaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Analyn Howells</last_name>
      <phone>314-251-1481</phone>
    </contact>
    <investigator>
      <last_name>George Matuschak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>SARS-CoV-2 Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

